Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Natural killer cells for cancer treatment
Company stage: Clinical
Diseases: Solid and haematological cancers
Genome editing tool: CRISPR-Cas9
Funding stage: Public (NASDAQ:NKTX)
Location: South San Francisco, CA, USA
Partners: CRISPR Therapeutics
Nkarta Therapeutics focuses on the development of natural killer (NK)-based cellular therapies. The company has developed a proprietary manufacturing platform that enables enhanced persistence, expansion and activity of NK and CAR-NK products. The company entered into a technology license agreement with CRISPR Therapeutics, that allows Nkarta to genetically modify its CAR-NK cell products. Furthermore, Nkarta and CRISPR Therapeutics are co-developing two programmes, one CAR-NK programme targeting CD70 and one combined NK + T cell programme.